Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Nat. Rev. Nephrol. doi: /nrneph

Advertisements

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 2 Pathology of scleroderma renal crisis

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.

Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Model of mechanosensation through primary cilia

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Differentiation and functional control of T-cell subsets

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Biologics that attenuate effector responses in the kidney

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Sources of data to characterize the ADPKD clinical phenotype

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Nat. Rev. Neurol. doi: /nrneurol

Targeting Immunity in End-Stage Renal Disease

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.18 Table 2 Current and evolving biologics relevant to autoimmune renal disease Holdsworth, S. R. et al. (2016) Biologics for the treatment of autoimmune renal diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.18

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.18 Table 2 Current and evolving biologics relevant to autoimmune renal disease Holdsworth, S. R. et al. (2016) Biologics for the treatment of autoimmune renal diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.18